GDC-0449: Phase II started

Roche's Genentech unit began an open-label, U.S. Phase II trial to evaluate once-daily 150 mg oral GDC-0449 for 12 weeks in about 50 patients. Roche has exclusive ex-U.S. rights to GDC-0449 from Genen...